Register for email alerts and news feeds:
This journal | BMJ Group
rss
Archives of Disease in Childhood 2005;90:801-806; doi:10.1136/adc.2004.056952
Copyright © 2005 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health.

ORIGINAL ARTICLE

Growth on stimulant medication; clarifying the confusion: a review

A Poulton

Correspondence to:
Correspondence to:
Dr A Poulton
Western Clinical School, Nepean Campus, The University of Sydney, Australia; sally_poulton{at}iinet.net.au

Aims: To get an overview of the studies of growth in height in children with attention deficit hyperactivity disorder (ADHD) treated with stimulant medication, to establish the consistencies and to try to resolve the discrepancies.

Methods: Twenty nine studies were reviewed following a Medline search: 22 related to children, six to late adolescents or adults, and one to children and adults.

Results: Children: Eleven studies gave results consistent with height attenuation on stimulant medication: eight were longitudinal, one was cross-sectional, and two showed growth rebound on ceasing medication. Studies with negative findings were inadequately powered (n = 3), lacked controls or statistical analysis (n = 3), measured height velocity without reference to treatment duration (n = 2), or used inappropriate growth parameters (n = 1), controls (n = 1), or normative data (n = 1). Late adolescents/adults treated with stimulant medication in childhood: Two studies associated childhood gastrointestinal side effects with attenuated late adolescent or adult height; all six cross-sectional studies had negative findings. The methodologies varied widely but there was some consistency in the degree of attenuation shown in studies with positive findings. The most sensitive methods analysed the changes in z-scores (standard deviation scores) or calculated the height deficits from paired measurements taken before and after an initial period of treatment with stimulant medication. The height deficit amounted to approximately 1 cm/year during the first 1–3 years of treatment.

Conclusions: Further research is needed into the causal mechanisms, the rate of physical maturation, and the long term implications for final stature.

Keywords: Attention deficit hyperactivity disorder; growth in height; dexamphetamine; methylphenidate; review


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • (2008). Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. Focus 6: 401-426 [Abstract] [Full Text]  
  • Ashton, H., Gallagher, P., Moore, B. (2006). The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder. J Psychopharmacol 20: 602-610 [Abstract]  
  • Panei, P., Knellwolf, A.-L., Arcieri, R., Vella, S. (2006). Absence of Unfavorable Effect of Atomoxetine on Growth in Pediatric Patients Is Still Not Demonstrated. Pediatrics 117: 587-588 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Latest from ADC

 

ADC is co-owned by the RCPCH and is the official journal of the European Academy of Paediatrics

BMJ Careers - Latest Paediatrics and Paediatric Surgery Jobs

Paediatrics and Paediatric Surgery Jobs